CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), especially anti- programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, have significantly improved the therapeutic scenario of advanced non-small-cell lung cancer (aNSCLC) [1].